UBS Group’s Lexicon Pharmaceuticals LXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $476K | Sell |
|
|||||
|
2025
Q2 | $379K | Sell |
|
|||||
|
2025
Q1 | $966K | Buy |
|
|||||
|
2024
Q4 | $507K | Buy |
|
|||||
|
2024
Q3 | $220K | Sell |
|
|||||
|
2024
Q2 | $271K | Sell |
|
|||||
|
2024
Q1 | $401K | Sell |
|
|||||
|
2023
Q4 | $260K | Buy |
|
|||||
|
2023
Q3 | $137K | Buy |
|
|||||
|
2023
Q2 | $223K | Sell |
|
|||||
|
2023
Q1 | $337K | Sell |
|
|||||
|
2022
Q4 | $305K | Buy |
|
|||||
|
2022
Q3 | $225K | Sell |
|
|||||
|
2022
Q2 | $395K | Buy |
|
|||||
|
2022
Q1 | $443K | Buy |
|
|||||
|
2021
Q4 | $378K | Buy |
|
|||||
|
2021
Q3 | $19K | Buy |
|
|||||
|
2021
Q2 | $9K | Sell |
|
|||||
|
2021
Q1 | $80K | Buy |
|
|||||
|
2020
Q4 | $46K | Buy |
|
|||||
|
2020
Q3 | $4K | Sell |
|
|||||
|
2020
Q2 | $54K | Buy |
|
|||||
|
2020
Q1 | $32K | Sell |
|
|||||
|
2019
Q4 | $201K | Buy |
|
|||||
|
2019
Q3 | $73K | Buy |
|
|||||
|
2019
Q2 | $48K | Buy |
|
|||||
|
2019
Q1 | $29K | Sell |
|
|||||
|
2018
Q4 | $1.18M | Buy |
|
|||||
|
2018
Q3 | $1.74M | Buy |
|
|||||
|
2018
Q2 | $1.47M | Sell |
|
|||||
|
2018
Q1 | $1.88M | Buy |
|
|||||
|
2017
Q4 | $1.11M | Sell |
|
|||||
|
2017
Q3 | $1.95M | Buy |
|
|||||
|
2017
Q2 | $2.19M | Buy |
|
|||||
|
2017
Q1 | $1.88M | Buy |
|
|||||
|
2016
Q4 | $1.66M | Buy |
|
|||||
|
2016
Q3 | $629K | Sell |
|
|||||
|
2016
Q2 | $802K | Buy |
|
|||||
|
2016
Q1 | $625K | Sell |
|
|||||
|
2015
Q4 | $1.91M | Buy |
|
|||||
|
2015
Q3 | $235K | Buy |
|
|||||
|
2015
Q2 | $125K | Buy |
|
|||||
|
2015
Q1 | $77K | Buy |
|
|||||
|
2014
Q4 | $46K | Buy |
|